Adenocarcinoma of corpus uteri

Adenocarcinoma of the corpus uteri is a malignant epithelial neoplasm originating primarily from the glandular lining of the endometrium within the upper body of the uterus

Adenocarcinoma of the corpus uteri is a malignant epithelial neoplasm originating primarily from the glandular lining of the endometrium within the upper body of the uterus It predominantly affects postmenopausal females and represents the most common gynecologic malignancy in developed regions Pathophysiologically, it most frequently arises as endometrioid adenocarcinoma linked to excess, unopposed estrogen stimulation, though less common, non-endometrioid subtypes—such as serous or clear cell ...

Adenocarcinoma of the corpus uteri is a malignant epithelial neoplasm originating primarily from the glandular lining of the endometrium within the upper body of the uterus Pathophysiologically, it most frequently arises as endometrioid adenocarcinoma linked to excess, unopposed estrogen stimulation, though less common, non-endometrioid subtypes—such as serous or clear cell adenocarcinomas—exhibit estrogen-independent oncogenesis driven by distinct genetic alterations like TP53 mutations

It predominantly affects postmenopausal females and represents the most common gynecologic malignancy in developed regions Clinically, it typically presents in early stages with abnormal uterine bleeding, such as postmenopausal bleeding or irregular vaginal discharge, but advanced disease may involve deep myometrial invasion, pelvic pain, or systemic metastasis

It predominantly affects postmenopausal females and represents the most common gynecologic malignancy in developed regions Pathophysiologically, it most frequently arises as endometrioid adenocarcinoma linked to excess, unopposed estrogen stimulation, though less common, non-endometrioid subtypes—such as serous or clear cell adenocarcinomas—exhibit estrogen-independent oncogenesis driven by distinct genetic alterations like TP53 mutations

Clinically, it typically presents in early stages with abnormal uterine bleeding, such as postmenopausal bleeding or irregular vaginal discharge, but advanced disease may involve deep myometrial invasion, pelvic pain, or systemic metastasis